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Background: Overweight has increased in many countries over the past 20 years and excessive body weight is an
established risk factor for adverse health outcomes and chronic diseases. This study aimed to determine
comorbidity associated with overweight and obesity in a nationally representative sample of German adults.
Methods: In the German National Health Interview and Examination Survey 1998 standardized measures of body
weight, height and waist circumference (WC) were obtained for 7,124 men and women 18 to 79 years of age.
Information on pre-existing health conditions, health-related behaviors, and sociodemographic characteristics was
collected using physician-administered computer-assisted interviews and self-administered questionnaires. World
Health Organization (WHO) cut-off criteria were applied to define overweight (BMI 25.0-29.9 kg/m2) and obesity
(BMI ≥30.0 kg/m2) and abdominal obesity (men: WC ≥102 cm; women: WC ≥88 cm).
Results: The crude prevalence of persons with cardiometabolic risk factors, diabetes mellitus, cardiovascular disease
(CVD), gall bladder disease, and osteoarthritis showed a significant stepwise increase from the lowest to the highest
BMI category in both sexes. In multiple logistic regression models adjusting for age, social status, and smoking,
significant associations with overweight and obesity persisted for cardiometabolic risk factors and osteoarthritis. For
example, obese persons had a three- to fourfold higher chance of having any cardiometabolic risk factor compared
to normal weight persons (odds ratio (OR) = 4.07, 95% CI: 3.16-5.25 for men; OR = 3.40 (2.60-4.46) for women). Only
in women, overweight and obesity as well as abdominal obesity, independent of BMI category, were significantly
and consistently associated with diabetes (overweight: OR = 1.85 (1.03-3.30); obesity: OR = 2.94 (1.63-5.31); abdominal
obesity: OR = 1.44 (1.08-1.92) and gall bladder disease (overweight: OR= 1.65 (1.22-2.25); obesity: OR= 3.06 (2.26-4.14);
abdominal obesity: OR= 1.73 (1.25-2.39)).
Conclusion: Current estimates of disease burden underline the public health importance and clinical relevance related
to overweight and obesity and needs to take into account comorbidity aspects.Background
Worldwide, the prevalence of persons with overweight
or obesity has increased in many countries over the past
20 years [1-4]. Excessive body weight is an established
risk factor for adverse health outcomes and chronic dis-
eases [5]. Obesity is not only associated with high blood
pressure [6,7], and type 2 diabetes [8,9], but also related
to cardiovascular diseases (CVD) independent of blood
pressure and lipid levels [10,11]. Results from the Health* Correspondence: schienkiewitza@rki.de
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Study identified obesity as a risk factor for gout [12,13].
High BMI levels are associated with an increased risk of
coronary heart disease [7,14,15] and ischemic stroke
[16]. In addition, increased BMI is an established risk
factor for several types of cancer [17,18]. A prospective
evaluation of the Nurses Health and Health Profes-
sionals Follow-up Study indicated a positive association
between abdominal adiposity and gallstone diseases in
women and men [19,20]. The relationship between
obesity and thyroid diseases is more complex as
hypothyroidism is associated with weight gain [21]. The
prospective Whitehall-II-Study reported results thatentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Schienkiewitz et al. BMC Public Health 2012, 12:658 Page 2 of 11
http://www.biomedcentral.com/1471-2458/12/658common mental disorders increase the risk for obesity,
but if participants with common mental disorders at
baseline were removed from the analysis, no association
between obesity and mental disorders could be found
[22]. Furthermore, obesity is directly related to osteo-
arthritis [23,24]. Obesity may also be an important risk
factor for allergic disease (e.g. allergic rhinoconjunctivi-
tis, allergic contact exzema, neurodermatitis, food al-
lergy, urticaria), but the relationship remains less clear
[25]. Several studies have reported a positive association
[26-28], whereas others did not find a relationship be-
tween obesity and atopy, hay fever, or serological mar-
kers of atopy [29,30].
The above mentioned references indicate that several
articles focus on single health outcomes. Only a few
studies have used nationally representative survey data
to systematically analyze the comorbidities of overweight
and obesity [31-33]. In the present study, we used data
from the 1998 German National Health Interview and
Examination Survey (GNHIES) to examine sex and age
specific associations between a large list of self-reported
chronic health conditions and overweight and obesity as
defined by measures of BMI and waist circumference
(WC).
Methods
Study design and study population
The German Health Interview and Examination Survey
(GNHIES) was conducted from October 1997 to March
1999 as a population-wide, nationally representative
cross-sectional survey including 7,124 participants
(3,450 men, 3674 women) aged 18 to 79 years. Sampling
procedures have previously been described in detail [34].
In brief, the population sample was derived in a two-
stage sampling procedure. First, a representative sample
of communities with respect to their size and federal
state was selected. Second, a random selection of non
institutionalized adults from local population registries
stratified by sex and 5-year-age groups was performed.
The overall response rate was 61.4% [35]. Approval for
the survey was given from the Federal Office for the
Protection of Data, Germany. Written informed consent
was obtained from all participants prior to the interview
and examination.
For the present analysis, we excluded a total of 86 par-
ticipants with missing information or invalid values on
anthropometric measurements (weight, height, waist cir-
cumference) as well as 25 persons, who did not
complete the computer assisted personal interview.
Multivariate analyses are based on a total of 6,790 parti-
cipants (3,320 men, 3,470 women) with complete data.
The number of participants in these analyses is slightly
reduced due to the exclusion of those who had missing
values on social status (n = 217) and smoking (n = 156).Anthropometric variables
Standardized measurements of body weight, body
height and waist circumference (WC) were conducted
with participants wearing only light clothing and no
shoes. Body weight was measured with a calibrated
electronic scale (type: SECA) to the nearest 0.1 kg and
body height was measured with a leveling board on
the electronic scale to the nearest 0.1 cm. WC was
measured using a flexible, non-stretchable measuring
tape to an accuracy of 0.1 cm. Body mass index
(BMI) was calculated as body weight (in kg) divided
by body height squared (in m). We applied World
Health Organization (WHO) recommended criteria to
define normal weight (BMI < 25 kg/m2), overweight
(BMI= 25.0-29.9 kg/m2) and obesity (BMI≥ 30.0 kg/m2)
and abdominal obesity based on WC (men: ≥102 cm;
women: ≥88 cm) [36].
Assessment of comorbidity
Using a standardized computer-assisted personal inter-
view (CAPI), specifically trained study physicians
obtained a detailed medical history and current medica-
tion use. Participants were asked whether a physician
had ever told them that they had the disease or health
problem, and when the particular health condition had
last been present (within the past four weeks; within the
past 12 months; more than 12 months ago; don’t know).
Current medication use was defined as any prescription
or over-the-counter (OTC) drug used within 7 days
prior to the survey interview. Participants were asked to
bring the original medication containers or prescriptions
to the survey centre for the purpose of verification. For
each medication brand name, daily dosage and duration
of use were documented and the ATC-(Anatomical
Therapeutic Chemical) codes were assigned [37].
For the present analysis, we used information
regarding the following 25 chronic health problems:
hypertension, hyperlipidemia, hyperuricemia/gout, dia-
betes mellitus, stroke, myocardial infarction (MI), angina
pectoris or other coronary heart disease (CHD), heart
failure, asthma, chronic bronchitis, gastritis or duoden-
itis, gastric or duodenal ulcer, gall bladder disease, cir-
rhosis of the liver, thyroid disease, any malignant disease,
any mental health problem (e.g. depression, anxiety dis-
order, psychosis), osteoarthritis, rheumatoid arthritis,
osteoporosis, allergic rhinitis, allergic contact exzema,
neurodermatitis, food allergy, urticaria. Etiologically or
clinically related health conditions were further grouped
into disease categories, such as cardiometabolic risk fac-
tors (hypertension, hyperlipidemia, hyperuricemia/gout);
CVD (stroke, MI, angina pectoris or other CHD, heart
failure); lower respiratory disease (asthma, chronic bron-
chitis); upper gastrointestinal tract disease (gastritis or
duodenitis; gastric or duodenal ulcer); musculoskeletal
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and atopic disease (allergic rhinitis, allergic contact
exzema, neurodermatitis, food allergy, urticaria). Atopic
disease did not consider allergic asthma, since differenti-
ation between allergic and non-allergic asthma was not
possible.
In order to assure capture of an ongoing health prob-
lem, the case definition of most of the considered health
conditions required that the disease or health problem
had ever been diagnosed by a doctor and that it had
been present during the 12 months prior to the survey
interview. Additional information on current drug use
was considered for hypertension (ATC-Code C02, C03,
C07, C08, C09), hyperlipidemia (ATC-Code C10), hyper-
uricemia (ATC-Code M04), diabetes (ATC-Code A10),
and thyroid diseases (ATC-Code H03). Participants on
relevant current medication were categorized as having
the particular health problem irrespective of self-
reported medical history. A lifetime medical history
(ever diagnosed by a doctor) regardless of the time of
last occurrence was used to define health conditions
likely to involve irreversible or progressive organ damage
(stroke, MI, angina pectoris or other CHD, any malig-
nant disease).
Covariates
Information on age, smoking habits (non-smoker, ex-
smoker or current smoker), education, household in-
come and professional status group was assessed using a
self-administered standardized questionnaire. A compos-
ite socio-economic status index was computed integrat-
ing information on educational level, income and
profession as previously described [38]. Scores from 1-7
were attributed to each of the components and the sum
of the scores was calculated ranging from a possible
minimum of 3 to a maximum of 21. Categories of social
status were defined lower (3-8), intermediate (9-14), and
upper (15-21).
Statistical analysis
All statistical analyses were performed with SAS release
9.2 (SAS Institute, Cary, NC). Tests were two-sided, and
P values <0.05 were considered statistically significant. A
survey specific weighting factor took into account differ-
ences in demographic characteristics from the official
German population according to age, gender, commu-
nity size and residence in East or West Germany result-
ing from the sample design. The sampling weight
ensured representative results from this sample for the
total population in order to assure representativeness at
the population level.
Statistical analyses were consistently stratified by gender.
Continuous variables were presented as mean and 95%
confidence intervals, categorical variables were expressedas a percentage of the population. Descriptive statistics
were used to assess the crude prevalence in percent and
95% confidence intervals (CI) of persons with chronic
health conditions by BMI and WC categories as defined
above. In case of aggregate disease categories, associations
were analyzed for disease groups as well as individual
health conditions within groups. The independent associ-
ation of overweight, obesity and abdominal obesity with
comorbidities was analyzed in multivariate logistic regres-
sion models adjusting for covariates which included age as
a continuous variable, and social status and smoking as
categorical variables. Separate models were fitted for each
health condition (dependent variable) and for overweight,
obesity or abdominal obesity (independent variable).
Odds ratios for the relationship between abdominal
obesity and health conditions are adjusted for covariates
as well as for BMI as a categorical variable. Interaction
between overweight, obesity or abdominal obesity and
age (< 50 vs. ≥ 50 years) was tested by adding the re-
spective product terms to the multivariate models. Age
specific estimates are presented where the interaction
term was statistically significant.
Results
One third of men and less than half of women had nor-
mal weight based on BMI measurements. 48% of men
fell into the overweight BMI category as compared to
31% of women. About 20% of men and women were
obese with a BMI of more than 30 kg/m2 (Table 1). The
prevalence of persons with overweight was consistently
higher among men than among women of all age
groups. In contrast, the prevalence of obesity in men
and women was quite similar up to an age of 60 years,
and was higher among women than men in older age
groups (Figure 1).
Overall 30% of men and 38% of women were classified
as having abdominal obesity. In all age groups, the over-
all prevalence of abdominal obesity rose from 1.2%
among normal weight men and 4.2% among normal
weight women to 26.4% and 48.5% in overweight men
and women, respectively, and to 88% and 96% among
obese men and women (data in detail not shown). The
prevalence of abdominal obesity was consistently higher
in women than men in all age and BMI strata. In nearly
all age groups, the majority of obese men and women
had abdominal obesity (Figure 2).
The crude prevalence of persons with any cardiometa-
bolic risk factor, diabetes, any CVD or osteoarthritis sig-
nificantly increased with overweight and obesity in both
sexes (Tables 2a and 2b). In women, this was also true
for the prevalence of gall bladder disease. Overweight
and obesity were not significantly associated with preva-
lent lower respiratory disease, upper gastrointestinal
tract disease, liver cirrhosis, thyroid disease, cancer,
Table 1 Baseline characteristics of the study population
Total Men Women
N 7013 3417 3596
Age (years) 46.2 (45.5 – 46.8) 45.0 (44.3 – 45.8) 47.3 (46.6 – 48.0)
BMI (kg/m2) 26.6 (26.5 – 26.8) 26.9 (26.8 – 27.1) 26.3 (26.1 – 26.6)
Waist circumference (cm) 90.6 (90.1 – 91.1) 96.4 (95.9 – 96.9) 85.0 (84.4 – 85.6)
(%)
Age groups (years)
18-19 2.7 2.9 2.6
20-29 15.3 16.2 14.5
30-39 21.8 23.0 20.7
40-49 18.2 18.8 17.6
50-59 17.0 17.3 16.8
60-69 15.0 14.5 15.5
70-79 9.9 7.4 12.3
Body Mass Index (kg/m2)
<25.0 40.3 33.2 47.2
25.0–29.9 39.4 48.0 31.2
30.0–34.9 15.4 15.7 15.1
≥35.0 4.9 3.1 6.5
Waist circumference (cm)
<94/80 41.1 41.9 40.3
94-102/80-88 25.0 28.4 21.7
≥102/88 33.9 29.7 38.0
Social status
Low 23.0 19.5 26.4
Middle 55.4 55.7 55.1
High 21.6 24.8 18.5
Smoking status
Current 32.6 37.2 28.2
Ex 21.7 28.3 15.3
Never 45.6 34.5 56.4
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other than osteoarthritis. Prevalent atopic disease was
inversely related with overweight and obesity in both
sexes, but a graded relationship across BMI categories
was observed only in men.
After adjustment for age, social status, and smoking,
both overweight and obesity were significantly associated
with cardiometabolic risk factors and osteoarthritis in
men and women (Table 3). Compared to men with nor-
mal weight, overweight men had an 84% higher chance
(OR= 1.84, 95% CI: 1.47; 2.31) and obese men had a
fourfold higher chance (OR=4.07, 95% CI; 3.16; 5.25) of
also having any cardiometabolic risk factor (Table 3).
Similarly, overweight men had a 1.4 higher odds (OR=
1.41 (1.12-1.78)) and obese men had a 2.1 higher odds
(OR= 2.14 (1.65-2.76)) of having osteoarthritis thannormal weight men. The strength of these associations
was similar albeit slightly weaker among women. Sex-
specific associations of overweight and obesity with car-
diovascular risk factors, but not with osteoarthritis were
stable across age strata, comparing persons below
50 years of age and those 50 years and older. Obesity
was associated with a significant 1.8-fold higher odds for
CVD among men and a 1.5-fold higher odds among
women. Only among women, overweight and obesity
were also positively associated with diabetes (OR= 1.85
(1.03-3.30) and OR=2.94 (1.63-5.31)) as well as gall
bladder disease (OR= 1.65 (1.22-2.25) and OR= 3.06
(2.26-4.14)). Atopic disease was inversely related to over-
weight in both sexes and with obesity in men. Results
persisted in sensitivity analyses excluding underweight































Figure 1 Prevalence of men (1a) and women (1b) with overweight (BMI 25.0-29.9 kg/m2) and obesity (BMI≥ 30 kg/m2) by age group.
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ity, independent of covariates and BMI categories, was
significantly and positively related to cardiometabolic
risk factors (OR= 1.44 (1.08-1.92)), diabetes (OR= 3.18
(1.69-5.99)) and gall bladder disease (OR= 1.73 (1.25-
2.39)), and significantly and inversely associated with
atopic disease (OR= 0.75 (0.59-0.95)). No significant as-
sociation of abdominal obesity with CVD or osteoarth-
ritis was observed in either sex (Table 3).
Discussion
This study presents estimates of the cross-sectional rela-
tionship between overweight and obesity and several
chronic conditions and diseases in a representative sam-
ple of German adults. The prevalence of overweight and
obesity increased with increasing age and the percentage
of men and women with abdominal obesity rose steadilywith age in overweight and even in the normal weight
persons, as defined by BMI.
The prevalence of the majority of chronic conditions
and diseases rose with increasing BMI. Both overweight
and obesity in men and women were significantly asso-
ciated with cardiometabolic risk factors and osteoarth-
ritis, which is consistent with findings from the
representative telephone survey (Behavioral Risk Factor
Surveillance System, BRFSS) in the United States among
adults aged 18 years and older [31]. This cross-sectional
study showed a strong association between overweight
and obesity, and cardiometabolic risk factors such as
high blood pressure, high cholesterol, and arthritis. Sev-
eral large cohort studies also found a direct positive as-
sociation between high BMI and hypertension [6,39],
and increased BMI and osteoarthritis [23]. A systematic
review and meta-analysis of prospective cohort studies
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Figure 2 Proportion of men (2a) and women (2b) with abdominal obesity (men≥ 102 cm; women≥ 88 cm) according to age group and
body mass index categories (normal weight: BMI < 25.0 kg/m2; overweight: BMI 25.0-29.9 kg/m2; obesity: BMI≥ 30.0 kg/m2).
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demonstrated a significant association between over-
weight and obesity with incident diabetes, CVD, asthma,
gallbladder disease, osteoarthritis, and various types of
cancer [40]. Furthermore, our survey results indicated a
positive association among men and women between
overweight and obesity and diabetes and gallbladder dis-
ease, which is also consistent with findings from large
cohort studies [8,9,19,20]. However, in our study, the re-
lationship between overweight and obesity and diabetes
and gallbladder disease was only significant amongwomen. The stronger association between obesity and
gallbladder disease has been observed in other studies,
but the reason still remains unclear [41,42]. The missing
significance between overweight and obesity and dia-
betes among men may be due to the lower prevalence of
diagnosed diabetes in men compared to women. The
diabetes diagnosis in our study based on a self-reported
physician diagnosis and the current drug use without
any blood glucose analyses. In Germany, the prevalence
of undiagnosed diabetes is higher among men than
among women [43,44]. Therefore, the true association
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could be underestimated.
The increased risk for CVD among overweight and
obese has been investigated in several prospective stud-
ies. In the Framingham Heart Study, a prospective co-
hort study with 44 years of follow-up, both men and
women with overweight had a two-fold higher, obese
men had a 1.46 times higher (95%-CI: 1.20-1.77) and
obese women a 1.64 times (1.37-1.98) higher risk for
CVD [7]. A meta-analysis of cohort studies including
more than 300.000 persons indicated a 30% higher risk
for CHD in overweight and an 80% higher risk in obeseTable 2 Prevalence (%, 95% CI) of self-reported physician-dia
German men (2a) and women (2b) 18-79 years of age
a. Men (N= 3.417)
BMI Total N
N 3417
1. Cardiometabolic risk factor
Hypertension 20.2 (18.6 – 21.9)
Hyperlipidamia 15.8 (14.4 – 17.4)
Hyperuricemia or gout 7.8 (6.9 – 8.8)
1 risk factor 31.1 (29.2 – 33.1) 1
2 risk factors 10.6 (9.6 – 11.8)
3 risk factors 2.1 (1.6 – 2.6)
2. Diabetes mellitus 4.2 (3.6 – 4.9)
3. Any CVD 8.8 (7.8 – 9.9)
Angina pectoris/other CHD 6.5 (5.7 – 7.5)
Myocardial infarction 3.3 (2.7 – 4.0)
Any CHD 7.3 (6.3 – 8.3)
Heart failure 2.4 (1.8 – 3.2)
Stroke 1.4 (1.1 – 1.9)
4. Any lower respiratory disease 7.5 (6.4 – 8.7)
Asthma 3.5 (2.9 – 4.3)
Chronic bronchitis 4.5 (3.7 – 5.5)
5. Any upper GIT disease 6.9 (6.0 – 7.8)
Gastritis/Duodenitis 6.6 (5.7 – 7.5)
Gastric/duodenal ulcer 1.3 (0.9 – 1.7)
6. Gall bladder disease 5.1 (4.3 – 6.1)
7. Cirrhosis of the liver 0.2 (0.1 – 0.4)
8. Thyroid disease 6.9 (6.0 – 8.0)
9. Any malignancy (cancer) 3.0 (2.5 – 3.7)
10. Mental health problem 4.2 (3.5 – 4.9)
11. Any musculoskeletal disease 28.9 (26.9 – 31.0) 1
Osteoarthritis 27.7 (25.6 – 29.8) 1
Rheumatoid arthritis 2.9 (2.3 – 3.6)
Osteoporosis 0.7 (0.5 – 1.1)
12. Atopic disease* 25.0 (23.4 – 26.6) 3men and women [14]. However, in our study the associ-
ation between overweight and CVD were neither signifi-
cant in men nor in women, and for obesity and CVD we
only observed a significant higher risk in men. The miss-
ing significance among women could be due to gender
disparities in the diagnosis of the underlying diseases in
the CVD group, in particular CHD. In fact, analyses by
subgroups confirmed that the observed sex difference is
related to CHD. More than a decade ago, when this sur-
vey was conducted, the diagnosis of CHD was a typical
male diagnosis and not very commonly diagnosed








8.5 (6.9 – 10.5) 21.3 (19.1 – 23.6) 38.1 (34.0 – 42.4)
8.3 (6.6 – 10.3) 17.8 (15.8 – 20.1) 24.0 (20.3 – 28.2)
2.2 (1.5 – 3.3) 8.7 (7.2 – 10.5) 15.2 (12.5 – 18.3)
5.0 (13.1 – 17.2) 34.1 (31.5 – 36.9) 52.0 (47.5 – 56.4)
3.7 (2.7 – 5.0) 11.4 (9.7 – 13.3) 21.0 (17.9 – 24.4)
0.4 (0.2 – 1.0) 2.3 (1.6 – 3.3) 4.3 (3.0 – 6.1)
2.1 (1.4 – 3.3) 4.8 (3.9 – 5.9) 6.4 (4.7 – 8.5)
4.2 (3.1 – 5.7) 10.2 (8.8 – 11.8) 13.4 (10.7 – 16.6)
2.7 (1.9 – 3.9) 7.6 (6.3 – 9.1) 10.6 (8.2 – 13.6)
0.9 (0.5 – 1.8) 3.7 (2.8 – 4.7) 6.3 (4.4 – 9.1)
3.1 (2.2 – 4.3) 8.3 (6.9 – 9.9) 12.1 (9.5 – 15.3)
1.0 (0.5 – 1.9) 2.9 (2.1 – 4.1) 3.7 (2.4 – 5.5)
0.9 (0.4 – 1.7) 1.8 (1.3 – 2.6) 1.4 (0.7 – 2.9)
7.1 (5.6 – 9.0) 7.1 (5.7 – 8.8) 9.1 (7.0 – 11.6)
3.6 (2.5 – 5.1) 3.2 (2.4 – 4.3) 4.3 (2.9 – 6.3)
3.9 (2.9 – 5.4) 4.7 (3.6 – 6.1) 5.1 (3.7 – 7.0)
6.5 (5.0 – 8.3) 7.1 (5.9 – 8.6) 7.0 (5.3 – 9.4)
6.0 (4.5 – 7.8) 6.8 (5.6 – 8.3) 6.8 (5.1 – 9.1)
1.5 (0.9– 2.4) 1.2 (0.8 – 1.9) 0.9 (0.4 – 2.1)
3.4 (2.4 – 4.7) 5.5 (4.4 – 6.9) 7.3 (5.3 – 9.9)
0.1 (0.0 – 0.7) 0.2 (0.1 – 0.6) 0.5 (0.2 – 1.6)
5.5 (4.2 – 7.2) 7.8 (6.5 – 9.5) 7.1 (5.3 – 9.4)
3.1 (2.1 – 4.3) 3.2 (2.3 – 4.3) 2.6 (1.5 – 4.5)
3.0 (2.1 – 4.3) 5.1 (4.1 – 6.4) 3.7 (2.4 – 5.5)
7.9 (15.4 – 20.7) 31.4 (28.5 – 34.4) 42.0 (37.3 – 46.8)
7.1 (14.7 – 19.9) 30.1 (27.2 – 33.0) 40.3 (35.7 – 45.0)
2.3 (1.5 – 3.5) 2.8 (2.0 – 4.0) 4.0 (2.6 – 6.1)
0.6 (0.2 – 1.4) 0.7 (0.4 – 1.3) 0.9 (0.4 – 2.0)
0.7 (27.8 – 33.8) 23.1 (21.0 – 25.4) 19.6 (16.6 – 22.9)
Table 2 Prevalence (%, 95% CI) of self-reported physician-diagnosed morbidities according to BMI categories among
German men (2a) and women (2b) 18-79 years of age (Continued)
b. Women (N=3.596)






N 3596 1690 1109 797
1. Cardiometabolic risk factor
Hypertension 24.9 (23.2 – 26.7) 10.1 (8.5 – 12.0) 30.0 (27.1 – 33.0) 49.7 (46.1 – 53.3)
Hyperlipidamia 16.4 (14.9 – 18.0) 10.9 (8.9 – 13.2) 19.2 (16.4 – 22.3) 24.5 (20.9 – 28.6)
Hyperuricemia or gout 3.9 (3.2 – 4.8) 1.0 (0.6 – 1.6) 4.5 (3.3 – 6.3) 9.4 (7.1 – 12.3)
1 risk factor 33.7 (31.8 – 35.6) 18.2 (16.0 – 20.7) 40.1 (36.8 – 43.6) 58.0 (54.5 – 61.5)
2 risk factors 10.0 (8.8 – 11.3) 3.6 (2.6 – 5.0) 11.7 (9.5 – 14.4) 21.4 (17.7– 25.5)
3 risk factors 1.6 (1.2 – 2.1) 0.2 (0.1 – 0.6) 1.8 (1.0 – 3.2) 4.2 (2.8 – 6.4)
2. Diabetes mellitus 4.9 (4.1 – 5.9) 1.6 (1.0– 2.5) 6.1 (4.6 – 8.0) 10.5 (8.1 – 13.5)
3. Any cardiovascular disease (CVD) 8.8 (7.5 – 10.2) 4.1 (3.2 – 5.4) 11.6 (9.0 – 14.8) 14.7 (11.8 – 18.2)
Angina pectoris/other CHD 5.2 (4.3 – 6.4) 2.3 (1.5 – 3.4) 7.0 (5.0 – 9.6) 9.2 (7.4 – 11.5)
Myocardial infarction 1.7 (1.2 – 2.3) 0.5 (0.2 – 1.1) 2.8 (1.7 – 4.5) 2.7 (1.7 – 4.1)
Any CHD 5.6 (4.6 – 6.9) 2.3 (1.6 – 3.5) 7.7 (5.6 – 10.6) 9.8 (7.8 – 12.2)
Heart failure 3.4 (2.8 – 4.2) 1.6 (1.1 – 2.6) 4.2 (3.1 – 5.7) 6.1 (4.2 – 8.8)
Stroke 1.7 (1.2 – 2.3) 0.7 (0.3 – 1.4) 2.5 (1.5 – 4.2) 2.5 (1.5 – 4.2)
4. Any lower respiratory disease 7.5 (6.6 – 8.6) 7.5 (6.2 – 9.1) 6.6 (4.9 – 8.8) 8.8 (6.7 – 11.4)
Asthma 4.1 (3.4 – 5.0) 4.3 (3.3 – 5.5) 4.0 (2.7 – 5.9) 4.0 (2.8 – 5.8)
Chronic bronchitis 4.3 (3.6 – 5.2) 4.0 (3.0 – 5.2) 3.5 (2.4 – 5.2) 6.0 (4.3 – 8.3)
5. Any upper GIT disease 8.6 (7.5 – 9.8) 8.8 (7.3 – 10.6) 7.7 (6.1 – 9.7) 9.4 (7.3 – 12.1)
Gastritis/Duodenitis 8.3 (7.2 – 9.4) 8.5 (7.0 – 10.2) 7.4 (5.8 – 9.4) 9.0 (6.9- 11.6)
Gastric/duodenal ulcer 1.1 (0.8 – 1.6) 1.0 (0.6 – 1.8) 0.9 (0.4 – 1.8) 1.6 (0.9- 2.7)
6. Gall bladder disease 15.0 (13.6 – 16.4) 6.9 (5.6 – 8.4) 17.4 (15.1 – 20.0) 29.0 (25.3 – 33.0)
7. Cirrhosis of the liver 0.1 (0.0 – 0.2) 0.1 (0.0 – 0.5) 0.1 (0.0 – 0.5) 0.1 (0.0 – 0.8)
8. Thyroid disease 26.2 (24.4 – 28.1) 24.1 (21.8 – 26.5) 28.6 (25.8 – 31.6) 27.4 (24.1 – 31.0)
9. Any malignancy (Cancer) 4.7 (3.9 – 5.6) 3.8 (2.8 – 5.1) 5.8 (4.4 – 7.4) 5.1 (3.4 – 7.4)
10. Mental health problem 9.2 (8.2 – 10.5) 8.2 (6.6 – 10.3) 10.0 (8.2 – 12.1) 10.4 (8.2 – 13.0)
11. Any musculoskeletal disease 33.1 (30.9 – 35.4) 22.5 (20.0 – 25.3) 40.0 (36.6 – 43.5) 46.3 (41.8 – 50.8)
Osteoarthritis 29.0 (26.7 – 31.3) 18.5 (16.1 – 21.3) 35.3 (31.6 – 39.1) 42.6 (37.9 – 47.4)
Rheumatoid arthritis 5.3 (4.3 – 6.3) 3.8 (2.8 – 5.1) 6.3 (4.8 – 8.3) 6.9 (5.1 – 9.3)
Osteoporosis 5.9 (5.0 – 7.0) 4.6 (3.6 – 5.8) 6.9 (5.3 – 8.8) 7.6 (5.7 – 10.0)
12. Atopic disease* 39.2 (36.9 – 41.5) 43.1 (40.1 – 46.2) 35.3 (32.4 – 38.4) 36.3 (32.1 – 40.8)
*Allergic rhinitis, allergic contact exzema, neurodermatitis, food allergy or urticaria; GIT = gastrointestinal tract; CHD = coronary heart disease.
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http://www.biomedcentral.com/1471-2458/12/658compared to other disease endpoints, and should be
interpreted with caution. The diagnosis stroke is prob-
ably under diagnosed in a national health survey, as par-
ticipants with serious diseases and disabilities would not
have participated.
Regarding obesity and allergic diseases the published lit-
erature is controversial and the reasons for inconsistent
study results remain unclear. Two non-representative
cross-sectional studies found an independent effect of
overweight on atopic diseases only among women, but
not among men. The Humboldt Study 2003 collecteddata from around 2000 18-79 year old Canadians [26]
and Kilpeläinen et al. 2006 included 10667 Finish stu-
dents aged 18-25 years [46]. In contrast, representative
data from the NHANES Survey 2005-2006 indicate that
obesity was not independently associated with atopy [30].
Nevertheless, our study indicated a significant inverse
association between abdominal obesity and atopic dis-
ease in women and overweight and obesity and atopy
in men. The differences between study findings might
be due to different underlying diagnosis criteria. In the
Humboldt Study 2003 allergic diseases were assessed by
Table 3 Association of self-reported physician-diagnosed morbidities and overweight, obesity and abdominal obesity
among German men and women 18-79 years of age















N 1089 1584 647 2287 1033
Any cardiometabolic risk factor 1.0 1.84 (1.47 - 2.31) 4.07 (3.16 - 5.25) 1.0 1.23 (0.95 - 1.60)
Age <50 years 1.0 2.19 (1.58 - 3.05) 4.28 (2.84 - 6.46)
Age ≥50 years 1.0 1.51 (1.07 - 2.12) 3.58 (2.41 - 5.32)
Diabetes mellitus 1.0 1.35 (0.81 - 2.28) 1.69 (0.91 - 3.15) 1.0 1.56 (0.95 - 2.57)
Any cardiovascular disease (CVD) 1.0 1.33 (0.89 - 2.0) 1.82 (1.13 - 2.93) 1.0 1.10 (0.73 - 1.64)
Gall bladder disease 1.0 1.13 (0.75 - 1.69) 1.50 (0.91 - 2.45) 1.0 0.97 (0.62 - 1.53)
Osteoarthritis 1.0 1.41 (1.12 - 1.78) 2.14 (1.65 - 2.76) 1.0 1.13 (0.87 - 1.46)
Age <50 years 1.0 1.57 (1.14 - 2.17) 2.35 (1.62 - 3.41)
Age ≥50 years 1.0 1.06 (0.80 - 1.40) 1.53 (1.06 - 2.22)
Atopic disease 1.0 0.79 (0.64 - 0.97) 0.67 (0.51 - 0.88) 1.0 1.11 (0.84 – 1.48)










N 1647 1069 754 2158 1312
Any cardiometabolic risk factor 1.0 1.48 (1.14 - 1.92) 3.40 (2.60 - 4.46) 1.0 1.44 (1.08 - 1.92)
Age <50 years 1.0 1.20 (0.85 - 1.70) 2.87 (2.02 - 4.09)
Age ≥50 years 1.0 1.59 (1.14 - 2.22) 3.66 (2.52 - 5.31)
Diabetes mellitus 1.0 1.85 (1.03 - 3.30) 2.94 (1.63 - 5.31) 1.0 3.18 (1.69- 5.99)
Any cardiovascular disease (CVD) 1.0 1.34 (0.82 - 2.19) 1.51 (0.97 - 2.34) 1.0 0.93 (0.51 – 1.70)
Gall bladder Disease 1.0 1.65 (1.22 - 2.25) 3.06 (2.26 - 4.14) 1.0 1.73 (1.25 - 2.39)
Osteoarthritis 1.0 1.38 (1.10 - 1.74) 1.65 (1.25 - 2.17) 1.0 1.12 (0.86 - 1.46)
Age <50 years 1.0 1.48 (1.06 - 2.08) 1.45 (0.99 - 2.14)
Age ≥50 years 1.0 1.24 (0.93 - 1.66) 1.53 (1.10 - 2.12)
Atopic disease 0.91 (0.76 - 1.09) 1.14 (0.91 - 1.42) 1.0 0.75 (0.59 – 0.95)
BMI = Body Mass Index WC = Waist Circumference.
* adjusted for age (continuous), social status, (low, middle, high), smoking (ex, never, current).
** adjusted for age (continuous), social status (low, middle, high), smoking (ex, never, current), and categories of BMI (<25 kg/m2, 25- < 30 kg/m2, ≥30 kg/m2).
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http://www.biomedcentral.com/1471-2458/12/658a questionnaire and skin prick test [26] and NHANES
used a positive immune essay test result to define atopy
[30]. The cross-sectional study with young Finns used a
physician diagnosis of allergic rhinitis or allergic conjunc-
tivitis and in our study participants were asked whether a
physician had ever told them that they had an atopic dis-
ease (e.g. allergic rhinitis, allergic contact exzema, neuro-
dermatitis, food allergy, urticaria). More research is
needed to clarify the comparability of different diagnosis
information.
As in the descriptive analyses of prevalence estimates
across BMI categories, we did not observe an independent
significant association of overweight and obesity with
lower respiratory disease, upper GIT disease, and cirrhosis
of the liver, thyroid disease, malignancy or mental health
problem in the multivariate analysis.
In fact, after adjustment for BMI, abdominal obesity
was associated with higher odds ratios for cardiometa-
bolic risk factors, diabetes mellitus and gall bladderdiseases, but the estimates did not show significance
among men. This might be due to the use of WHO
recommendations for the sex specific cut-offs for high
risk WC (men: ≥102 cm; women: ≥88 cm) [36]. Al-
though results from a longitudinal cohort study showed
that even WC values below these cut-offs are associated
with increased risk of diabetes in men and women, it
could be that the thresholds for men might be inappro-
priately set to detect significant associations between
WC and cardiometabolic risk factors and diabetes melli-
tus [47]. Furthermore, while men had larger mean values
for WC compared to women the percentage of men with
abdominal obesity is lower than among women. It seems
that the used WC cut-off is a better predictor among
women compared to men.
To our knowledge, the relationship between weight
status and prevalence of different conditions and chronic
diseases has not been described for the German popula-
tion. These presented results are an important baseline
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http://www.biomedcentral.com/1471-2458/12/658investigation for further longitudinal analyses of upcom-
ing representative data from the next survey. This survey
includes participants of GNHIES and, therefore, will
allow us to compare the obesity associated disease bur-
den between two surveys at different time points
(1997-1999 and 2008-2011) of the last decade.
Our study has several limitations. First, the presented
data on comorbidity of overweight and obesity is
restricted to the population 18 to 79 years. Thus, our
results cannot be generalized to persons 80 years of age
and older. Second, given the cross-sectional design, the
results of the present study do not permit any conclu-
sions on causality or causal directions between obesity
and comorbidities. Third, the use of self-reports to iden-
tify chronic diseases can lead to recall and misclassifica-
tion bias. Self-reports have been widely used in
epidemiological studies to assess the burden of chronic
diseases. For most conditions specificity of self-reported
information is high, in particular if additional informa-
tion on medication use is used for internal validation
[48]. In the present study, we considered medication use
for hypertension, hyperlipidemia, hyperuricemia, dia-
betes, and thyroid disease. We cannot exclude, however,
that we missed participants with undiagnosed or sub-
clinical disease. For example, we only considered a
physician-diagnosed “mental health problem” and did
not use additional information based on the World
Mental Health Composite Diagnostic Interview adminis-
tered in a subset of the study population [49]. We also
did not consider the available blood pressure or serum
lipid measurements, because objective measurements to
define subclinical or previously undiagnosed disease
were available for only some conditions. Finally, it is
possible that selection and survivor bias contributed
to underestimate the burden of comorbidity asso-
ciated with overweight and obesity. In particular,
men and women with serious conditions likely to
cause irreversible organ damage, such as stroke or
malignancy would be expected to be under-represented
in this national survey.
In addition, BMI is a fairly blunt instrument through
which to define overweight and obesity and does not ad-
equately reflect body composition, especially unfavorable
fat mass distribution. BMI does not discriminate be-
tween body fat mass and lean tissue mass and it is pos-
sible that we have underestimated the abdominal fatness
in older individuals, who have higher percentages of fat
in relation to lean muscle mass compared to younger
men and women. Therefore, we analyzed WC as a mar-
ker for abdominal fat mass.
Despite these limitations the results of the present
study are based on a large nationally representative sam-
ple of 18-79 year old adults in Germany and a selection
bias can be neglected. Our cross-sectional results oncomorbidity of overweight and obesity are in line with
large prospective studies focusing on single health out-
comes, and the above mentioned biases might not affect
our results substantially.
Conclusion
This study provides nationally representative data on
comorbidity of overweight and obesity in Germany.
Current classification systems of obesity focus only on
anthropometric measures and should be complemented
by information on presence or extent of comorbidities,
e.g. Edmonton obesity staging system [50]. Obesity as a
major cause of morbidity is a substantial public health
problem with economic impact [51]. Co-occurring
chronic health problems affect more than half of the eld-
erly population [52], and will thereby led to an increas-
ing burden of disease associated with overweight and
obesity.
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